CONTENTS
Issue 74 | September 2018
How can big pharma restore its credibility in the eyes of patients and policymakers?
Exploring the highs and lows of
the world’s bestselling drug, Humira
We examine Bluebird Bio's innovative technology and business model
What can be done to improve the understanding of chronic migraine?
Why has ISPE gone down the philanthropic route with its new foundation?
Analysts from GlobalData break down the key trends and innovations in pharma
Life sciences firms need to adapt how they approach data management
The industry is undergoing dramatic change as new tech brings disruption